| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 7 and exclusion criteria 10. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | naloxone (Ventizolve®) |
| Formulation | 1.26 mg nasal spray |
| Reference number | 5033 |
| Indication | Ventizolve is intended for immediate administration as emergency therapy for known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression, in both non-medical and healthcare settings. Ventizolve is indicated in adults. Ventizolve is not a substitute for emergency medical care |
| Company | Accord Healthcare |
| BNF chapter | Central nervous system |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 08/12/2021 |